IDENTIFYING RESPIRATORY VACCINE ATTRIBUTES DRIVING PATIENT PREFERENCE: AN AI-SUPPORTED TARGETED LITERATURE REVIEW
Author(s)
Sarolta Borbely, MSc1, Jose Luis Bartelt Hofer, PhD2.
1Sanofi, Budapest, Hungary, 2Global Director HE&OR Vaccines, Sanofi Vaccines, Lyon, France.
1Sanofi, Budapest, Hungary, 2Global Director HE&OR Vaccines, Sanofi Vaccines, Lyon, France.
OBJECTIVES: This targeted literature review (TLR) aimed to synthesize evidence from stated preference studies in influenza, COVID-19 and respiratory syncytial virus (RSV) to identify the most salient vaccine characteristics behind individual preferences.
METHODS: A TLR was conducted in PubMed in November 2025 using disease-specific and methodological search strings related to conjoint analyses, followed by AI pre-screening (AIscreenR package) and extraction (NotebookLM software) with full or sample (~5%) manual verifications. Extracted were general study characteristics, vaccine attributes, their levels and relative importance (RI) values from a patient or healthcare provider (HCP) perspectives. Attribute clusters were created to group conceptually similar characteristics and facilitate the identification of dominant ones based on frequency of inclusion and RI.
RESULTS: Out of 2,730 identified records, 38 studies met the eligibility criteria. 38/38 studies included patient populations, only 1/38 a HCP cohort. Majority of studies assessed COVID-19 (n=32), followed by influenza (n=6) and RSV (n=1) vaccinations, and were mostly conducted in Asia (n=22) and Europe (n=13). Results of the synthesis revealed that the most frequently included attributes were vaccine efficacy (n=38), followed by safety (n=35), duration of protection (n=25), origin (brand/country) (n=18), and cost (n=17), among others. Studies that reported RI values (n=13) presented efficacy (RI:1.2%-56.1%) and safety (RI:2.4%-28%) as the main drivers of vaccine preference. The RI of other attributes varied depending on study methodology, country, and other population characteristics. The use of AI proved accurate for screening and basic text data extraction.
CONCLUSIONS: TLR results showed that efficacy and safety are the main determinants behind respiratory vaccine preference. The RI of other vaccine features is context-dependent and determined by factors such as setting, population characteristics, and study quality, notably the studies’ attribute selection. These factors denote the need to account for all contextual factors and to improve the scientific rigor across stated preference studies on respiratory vaccines.
METHODS: A TLR was conducted in PubMed in November 2025 using disease-specific and methodological search strings related to conjoint analyses, followed by AI pre-screening (AIscreenR package) and extraction (NotebookLM software) with full or sample (~5%) manual verifications. Extracted were general study characteristics, vaccine attributes, their levels and relative importance (RI) values from a patient or healthcare provider (HCP) perspectives. Attribute clusters were created to group conceptually similar characteristics and facilitate the identification of dominant ones based on frequency of inclusion and RI.
RESULTS: Out of 2,730 identified records, 38 studies met the eligibility criteria. 38/38 studies included patient populations, only 1/38 a HCP cohort. Majority of studies assessed COVID-19 (n=32), followed by influenza (n=6) and RSV (n=1) vaccinations, and were mostly conducted in Asia (n=22) and Europe (n=13). Results of the synthesis revealed that the most frequently included attributes were vaccine efficacy (n=38), followed by safety (n=35), duration of protection (n=25), origin (brand/country) (n=18), and cost (n=17), among others. Studies that reported RI values (n=13) presented efficacy (RI:1.2%-56.1%) and safety (RI:2.4%-28%) as the main drivers of vaccine preference. The RI of other attributes varied depending on study methodology, country, and other population characteristics. The use of AI proved accurate for screening and basic text data extraction.
CONCLUSIONS: TLR results showed that efficacy and safety are the main determinants behind respiratory vaccine preference. The RI of other vaccine features is context-dependent and determined by factors such as setting, population characteristics, and study quality, notably the studies’ attribute selection. These factors denote the need to account for all contextual factors and to improve the scientific rigor across stated preference studies on respiratory vaccines.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
PCR260
Topic
Clinical Outcomes, Medical Technologies, Patient-Centered Research
Topic Subcategory
Patient Behavior and Incentives
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Vaccines